Regn investors have opportunity to lead regeneron pharmaceuticals, inc. securities fraud lawsuit

New york , jan. 31, 2025 /prnewswire/ -- rosen law firm, a global investor rights law firm, reminds purchasers of securities of regeneron pharmaceuticals, inc. (nasdaq: regn) between november 2, 2023 and october 30, 2024, both dates inclusive (the "class period"), of the important march 10, 2025 lead plaintiff deadline. so what: if you purchased regeneron securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
REGN Ratings Summary
REGN Quant Ranking